Excretion of technetium 99m hexakismethoxyisobutylisonitrile in milk

dc.contributor.authorRubow S.M.
dc.contributor.authorEllmann A.
dc.contributor.authorLe Roux J.
dc.contributor.authorKlopper J.
dc.date.accessioned2011-05-15T16:16:20Z
dc.date.available2011-05-15T16:16:20Z
dc.date.issued1991
dc.description.abstractThe amount of radioactivity excreted in breast milk following the administration of technetium 99m hexakismethoxyisobutylisonitrile (99mTc-MIBI) to a patient referred for cold spot myocardial scintigraphy was determined. During the first 24 h after administration, only 41.2 kBq 99mTc (0.0084% of the injected dose) was excreted in 448 ml milk with the highest concentration of 0.49 kBq/ml in the first sample. The images obtained show a high concentration of 99mTc-MIBI in the lactating breasts contrary to the very small percentage excreted in the milk. Comparison with various recommendations regarding nursing after administration of radiopharmaceuticals seems to indicate that the administration of 99mTc-MIBI does not necessitate an interruption of breast-feeding.
dc.description.versionArticle
dc.identifier.citationEuropean Journal of Nuclear Medicine
dc.identifier.citation18
dc.identifier.citation5
dc.identifier.issn03406997
dc.identifier.urihttp://hdl.handle.net/10019.1/13738
dc.subjectmethoxy isobutyl isonitrile technetium tc 99m
dc.subjectadult
dc.subjectarticle
dc.subjectbreast feeding
dc.subjectbreast milk
dc.subjectcase report
dc.subjectfemale
dc.subjectheart scintiscanning
dc.subjecthuman
dc.subjectintravenous drug administration
dc.subjectAdult
dc.subjectBreast Feeding
dc.subjectCase Report
dc.subjectFemale
dc.subjectHuman
dc.subjectMilk, Human
dc.subjectMyocardial Infarction
dc.subjectNitriles
dc.subjectOrganotechnetium Compounds
dc.subjectPuerperal Disorders
dc.subjectSupport, Non-U.S. Gov't
dc.subjectTechnetium Tc 99m Sestamibi
dc.titleExcretion of technetium 99m hexakismethoxyisobutylisonitrile in milk
dc.typeArticle
Files